Gülcicegi Dilan Elcin, Hannemann Jonathan, Bürger Martin, Allo Gabriel, Dittmann Eva, Martin Anna, Jaspers Natalie, Holzapfel Bianca, Chon Seung-Hun, Lang Sonja, Goeser Tobias, Steffen Hans-Michael, Kasper Philipp
Department of Gastroenterology and Hepatology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
Department of General, Visceral, Tumor, and Transplantation Surgery, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
Front Med (Lausanne). 2024 Nov 25;11:1475997. doi: 10.3389/fmed.2024.1475997. eCollection 2024.
Acute decompensation (AD) in patients with liver cirrhosis is associated with a dramatic deterioration in prognosis. Immediate initiation of appropriate recompensation measures is essential to improve patient's outcome, although objective parameters for evaluating the success of recompensation are still lacking. Spleen stiffness measurements (SSM) have emerged as promising non-invasive tool to assess clinically significant portal hypertension (CSPH), which is the main driver of acute decompensation. However, while SSM accurately predicts CSPH and its complication, currently no data are available on its diagnostic performance during recompensation. This pilot-study aimed at evaluating changes in spleen stiffness following the initiation of recompensation measures in cirrhotic patients hospitalized due to AD.
In this prospective pilot-study, 60 patients with cirrhosis showing AD were included. Liver stiffness measurements (LSM) and SSM were performed on admission and repetitive SSM on day 3 and 5, respectivele, during recompensation measures. A cohort of patients ( = 10) with compensated cirrhosis served as control.
A total of 36 data sets from the originally enrolled 60 patients were eligible for final analysis. On admission, patients with AD revealed a significantly increased spleen stiffness compared to the control group (70.51 vs. 29.06 kPa, < 0.0001). Following the initiation of recompensation measures SSM revealed a significant reduction in spleen stiffness compared to the baseline assessment on day 3 (-18.5 kPa, -21.53%; = 0.0002) with no further decrease on day 5 (-17.63 kPa, -21.23%; = 0.0326).
Repetitive SSM seems to be a useful non-invasive clinical marker to assess the effectiveness of recompensation measures in cirrhotic patients with AD.
肝硬化患者的急性失代偿(AD)与预后的急剧恶化相关。立即启动适当的代偿措施对于改善患者预后至关重要,尽管仍缺乏评估代偿成功的客观参数。脾脏硬度测量(SSM)已成为评估具有临床意义的门静脉高压(CSPH)的有前景的非侵入性工具,而CSPH是急性失代偿的主要驱动因素。然而,虽然SSM能准确预测CSPH及其并发症,但目前尚无关于其在代偿期间诊断性能的数据。这项前瞻性研究旨在评估因AD住院的肝硬化患者启动代偿措施后脾脏硬度的变化。
在这项前瞻性研究中,纳入了60例出现AD的肝硬化患者。在入院时进行肝脏硬度测量(LSM)和SSM,并在代偿措施期间分别于第3天和第5天重复进行SSM。一组代偿期肝硬化患者(n = 10)作为对照。
最初纳入的60例患者中共有36个数据集符合最终分析要求。入院时,AD患者的脾脏硬度明显高于对照组(70.51 vs. 29.06 kPa,P < 0.0001)。启动代偿措施后,与第3天的基线评估相比,SSM显示脾脏硬度显著降低(-18.5 kPa,-21.53%;P = 0.0002),第5天无进一步下降(-17.63 kPa,-21.23%;P = 0.0326)。
重复进行SSM似乎是评估AD肝硬化患者代偿措施有效性的一种有用的非侵入性临床指标。